DNMT

Epigenetic Therapeutics Global Markets Research 2023-2028 Featuring Major Players - AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 2, 2024
Pharmaceutical, Health, Oncology, AstraZeneca, Breast cancer, Ovarian cancer, IDH, Prevalence, Bristol Myers Squibb, HDAC, Cancer, GSK, Epigenomics, COVID-19, Ageing, KMT, Growth, Row, DNMT, Environment, Pharmaceutical industry

The global epigenetic therapeutics market was valued at $6.4 billion in 2022.

Key Points: 
  • The global epigenetic therapeutics market was valued at $6.4 billion in 2022.
  • Technological innovations in epigenetic drug discovery and development are driving increased use of epigenetic therapeutics, which also is pushing market growth.
  • This report is a comprehensive study of the global market for epigenetic therapeutics.
  • This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

2023 Urology Care Foundation Research Scholar Awardees Announced

Retrieved on: 
Tuesday, December 19, 2023
University, Vanderbilt University Medical Center, Cancer, Ageing, Urology, Pelvic pain, Houston Methodist Hospital, Spinal cord, The, EZH2, Randomized controlled trial, System, DNMT, Memorial, Weill Cornell Medicine, Children, Patient, American Urological Association, Hospital, FACS, Ureteroscopy, Research, Cornell University, AUA, Prostate cancer, Doctor of Philosophy, Macrophage, Funding of science, Children's Hospital of Philadelphia, Nursing

BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.

Key Points: 
  • BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.
  • Research Scholar Awards support future research leaders and ensure they receive the necessary training and guidance for a successful research career.
  • "The Urology Care Foundation is dedicated to improving urologic health worldwide by supporting research, providing patient education materials, and promoting humanitarian initiatives,” said Harris M Nagler, MD, FACS, Urology Care Foundation President.
  • “We are proud of our 2023 awardees and recognize the substantial impact their work will have on advancing the field of urology.”
    To learn more about the Urology Care Foundation Research Scholar Awards visit: https://www.auanet.org/research-and-data/research-awards/aua-funding/res...

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Drug development, Communication, Mutation, AML, Plasma protein binding, NASDAQ, GLOBE, Company, Food, Patient, DNMT, Lymphoid leukemia, Review, ITD, Acute myeloid leukemia, FDA, GMP, SYK, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene family, Fast Track, Hematology, Exchange, Lymphatic system, MDS, TSX, JAK, U.S. Securities and Exchange Commission, Research, SAN, FLT3, Toxic leukoencephalopathy, APS, TKD, Pharmaceutical industry

Currently, an international Phase 1/2 clinical trial is ongoing for HM43239 in the R/R AML patient population.

Key Points: 
  • Currently, an international Phase 1/2 clinical trial is ongoing for HM43239 in the R/R AML patient population.
  • HM43239 received orphan drug designation from the FDA for treatment of acute myeloid leukemia in 2018.
  • Fast Track designation will help facilitate the drugs development.
  • Once a drug receives Fast Track designation, early and frequent communication between the FDA and the sponsor is encouraged throughout the entire drug development and review process.